MustGrow Biologics (CSE: MGRO) has begun testing its proprietary mustard-based formulation against Panama Disease, a pathogen that has been ravaging the global banana industry. The laboratory testing, to take place in Colombia, will look to provide a treatment for the pathogen.
The testing of TerraMG bio-pesticide for use against Panama Disease is a result of the formulation being proven to control soil-borne pathogens similar to the disease. Independent studies have shown that the product has had 100% control of Fusarium oxysporum, a relative of the disease commonly referred to as Panama disease.
Panama disease is a soil-borne pathogen that can remain in soil for decades, and for which there is currently no effective treatment available. The disease is so devastating that it can result in 100% yield loss, threatening the livelihoods of farmers. The disease threatens the entire $25 billion global banana industry, with the country of Colombia declaring a national state of emergency last year in connection to the disease. It has a particular affinity for the cavendish banana, the most commonly consumed banana globally for which approximately half of all global banana production consists of.
Laboratory results from the study are expected in the fourth quarter of 2020. MustGrow is presently looking to build on its existing field data to achieve registrational labels in Colombia and other South American agricultural industries. The company has been working towards registration in both the US and Canada for TerraMG, as it looks to receive approval for the formulation as a treatment of soil-borne pests and disease for high value crops.
MustGrow Biologics last traded at $0.36 on the CSE.
FULL DISCLOSURE: MustGrow Biologics Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover MustGrow Biologics Corp on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
